Sector News

GlaxoSmithKline soon to name RBS chair Hampton as next chairman

September 24, 2014
Life sciences
The folks looking for a switcheroo at the top of GlaxoSmithKline may get their wish by the weekend. Sources tell Sky News that GSK is set to name a new chairman to replace Christopher Gent: Philip Hampton, now chairman at Royal Bank of Scotland and a widely reported frontrunner for the GSK job.
 
The change might pacify investors who have been agitating for a GlaxoSmithKline shake-up since the company reported a big hit to sales last quarter, thanks to competition for its respiratory blockbuster Advair. Shareholders say they’re none too happy with Glaxo’s current image problem, either, with a $500 million bribery fine coming due in China and corruption probes active in a number of other countries.
 
On the other hand, investors looking for a chairman ready to step in and make a difference could be disappointed. According to Sky News, Hampton wouldn’t join Glaxo’s board till the end of the year, and wouldn’t actually take Gent’s seat till the company’s annual meeting in May.
 
Glaxo wouldn’t confirm, but says its succession planning for Gent is “well underway.”
 
Hampton would have a tough job ahead if he does sign on at Glaxo. Besides the slump in Advair sales, early results from its follow-ups, Anoro and Breo, have been less than spectacular. Glaxo warned in July that its profits forecast might be too ambitious. GSK shares plummeted on that news, taking a multibillion-dollar chunk out of the company’s market cap.
 
Meanwhile, Glaxo’s big asset-sale-and-swap with Novartis won’t close till next year, and the payoff won’t be immediate in any case. Off-loading its older products as planned will hit overall sales, at least at first.
 
GSK could use the proceeds of that established-products sale to make some deals, which might offer a ray of hope. The company might be counting on Hampton’s appointment to provide a bigger one. Whether investors see it the same way–and consider it to be enough of a change for the moment–remains to be seen.
 
By Tracy Staton
 

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend